c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

Cancer Letters

Volumn 225, Issue 1, 2005, Pages 1-26

  Christensen, James G ^a   Burrows, Jon ^c   Salgia, Ravi ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

c Met; HGF; Kinase; Oncogene

Indexed keywords

5 D 5; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; GEFITINIB; GELDANAMYCIN; IMATINIB; K 252A; KIRIN; LIGAND; NK 4; PHA 665752; RIBOZYME; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SU 11271; SU 11274; SU 11606; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER; CANCER THERAPY; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CELL TRANSFORMATION; CORRELATION ANALYSIS; DIMERIZATION; DRUG TARGETING; GENE AMPLIFICATION; GENE MUTATION; GENETIC CODE; GENETIC ENGINEERING; HUMAN; KIDNEY TUBULE CELL; NONHUMAN; ORGANOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTO ONCOGENE; RECEPTOR AFFINITY; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

MAMMALIA;

EID: 19544389146     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.09.044     Document Type: Review

References (224)

1. A.D. Laird, and J.M. Cherrington Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents Expert. Opin. Investig. Drugs 12 2003 51 64
2. L. Naldini, K.M. Weidner, E. Vigna, G. Gaudino, A. Bardelli, C. Ponzetto, and G.K. Michalopoulos Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor Eur. Mol. Biol. Org. J. 10 1991 2867 2878
3. D.P. Bottaro, J.S. Rubin, D.L. Faletto, A.M. Chan, T.E. Kmiecik, G.F. Vande Woude, and S.A. Aaronson Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product Science 251 1991 802 804
4. M.F. Di Renzo, R.P. Narsimhan, M. Olivero, S. Bretti, S. Giordano, and E. Medico Expression of the Met/HGF receptor in normal and neoplastic human tissues Oncogene 6 1991 1997 2003
5. E. Sonnenberg, D. Meyer, K.M. Weidner, and C. Birchmeier Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development J. Cell Biol. 123 1993 223 235
6. F. Bladt, D. Riethmacher, S. Isenmann, A. Aguzzi, and C. Birchmeier Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud [see comment] Nature 376 1995 768 771
7. C. Schmidt, F. Bladt, S. Goedecke, V. Brinkmann, W. Zschiesche, and M. Sharpe Scatter factor/hepatocyte growth factor is essential for liver development Nature 373 1995 699 702
8. I. Tsarfaty, S. Rong, J.H. Resau, S. Rulong, P.P. da Silva, and G.F. Vande Woude The Met proto-oncogene mesenchymal to epithelial cell conversion Science 263 1994 98 101
9. P.M. Comoglio, and C. Boccaccio Scatter factors and invasive growth Semin. Cancer Biol. 11 2001 153 165
10. W. Jiang, S. Hiscox, K. Matsumoto, and T. Nakamura Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer Crit. Rev. Oncol.-Hematol. 29 1999 209 248
11. L. Naldini, E. Vigna, R. Ferracini, P. Longati, L. Gandino, M. Prat, and P.M. Comoglio The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation Mol. Cell. Biol. 11 1991 1793 1803
12. G.A. Rodrigues, and M. Park Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase Oncogene 9 1994 2019 2027
13. C. Ponzetto, A. Bardelli, Z. Zhen, F. Maina, P. dalla Zonca, and S. Giordano A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family Cell 77 1994 261 271
14. T.M. Fournier, L. Lamorte, C.R. Maroun, M. Lupher, H. Band, W. Langdon, and M. Park Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion Mol. Biol. Cell 11 2000 3397 3410
15. K.A. Furge, Y.W. Zhang, and G.F. Vande Woude Met receptor tyrosine kinase: enhanced signaling through adapter proteins Oncogene 19 2000 5582 5589
16. M. Sachs, H. Brohmann, D. Zechner, T. Muller, J. Hulsken, and I. Walther Essential role of Gab1 for signaling by the c-Met receptor in vivo J. Cell Biol. 150 2000 1375 1384
17. K.M. Weidner, S. Di Cesare, M. Sachs, V. Brinkmann, J. Behrens, and W. Birchmeier Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis Nature 384 1996 173 176
18. S. Giordano, S. Corso, P. Conrotto, S. Artigiani, G. Gilestro, and D. Barberis The semaphorin 4D receptor controls invasive growth by coupling with Met Nat. Cell Biol. 4 2002 720 724
19. L. Trusolino, A. Bertotti, and P.M. Comoglio A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth Cell 107 2001 643 654
20. R. van der Voort, T.E. Taher, V.J. Wielenga, M. Spaargaren, R. Prevo, and L. Smit Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met J. Biol. Chem. 274 1999 6499 6506
21. H. Gu, and B.G. Neel The 'Gab' in signal transduction Trends Cell Biol. 13 2003 122 130
22. C.R. Maroun, M. Holgado-Madruga, I. Royal, M.A. Naujokas, T.M. Fournier, A.J. Wong, and M. Park The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase Mol. Cell. Biol. 19 1999 1784 1799
23. R.M. Day, V. Cioce, D. Breckenridge, P. Castagnino, and D.P. Bottaro Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis Oncogene 18 1999 3399 3406
24. K. Nakanishi, J. Fujimoto, T. Ueki, K. Kishimoto, T. Hashimoto-Tamaoki, and J. Furuyama Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase Clin. Exp. Metastatis 17 1999 507 514
25. S. Potempa, and A.J. Ridley Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly Mol. Biol. Cell 9 1998 2185 2200
26. S. Fan, Y.X. Ma, J.A. Wang, R.Q. Yuan, Q. Meng, and Y. Cao The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase Oncogene 19 2000 2212 2223
27. G.H. Xiao, M. Jeffers, A. Bellacosa, Y. Mitsuuchi, G.F. Vande Woude, and J.R. Testa Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways Proc. Natl Acad. Sci. USA 98 2001 247 252
28. I. Royal, N. Lamarche-Vane, L. Lamorte, K. Kaibuchi, and M. Park Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation Mol. Biol. Cell 11 2000 1709 1725
29. A. Kodama, K. Takaishi, K. Nakano, H. Nishioka, and Y. Takai Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells Oncogene 18 1999 3996 4006
30. A.J. Ridley, P.M. Comoglio, and A. Hall Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells Mol. Cell. Biol. 15 1995 1110 1122
31. L. Lamorte, S. Rodrigues, V. Sangwan, C.E. Turner, and M. Park Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts Mol. Biol. Cell 14 2003 2818 2831
32. L. Lamorte, I. Royal, M. Naujokas, and M. Park Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions Mol. Biol. Cell 13 2002 1449 1461
33. L. Lamorte, D.M. Kamikura, and M. Park A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein Oncogene 19 2000 5973 5981
34. D. Sakkab, M. Lewitzky, G. Posern, U. Schaeper, M. Sachs, W. Birchmeier, and S.M. Feller Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL J. Biol. Chem. 275 2000 10772 10778
35. J.F. Lai, S.C. Kao, S.T. Jiang, M.J. Tang, P.C. Chan, and H.C. Chen Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells J. Biol. Chem. 275 2000 7474 7480
36. H.C. Chen, P.C. Chan, M.J. Tang, C.H. Cheng, and T.J. Chang Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation J. Biol. Chem. 273 1998 25777 25782
37. C. Boccaccio, M. Ando, L. Tamagnone, A. Bardelli, P. Michieli, C. Battistini, and P.M. Comoglio Induction of epithelial tubules by growth factor HGF depends on the STAT pathway Nature 391 1998 285 288
38. P. Gual, S. Giordano, T.A. Williams, S. Rocchi, E. Van Obberghen, and P.M. Comoglio Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis Oncogene 19 2000 1509 1518
39. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat. Rev. Mol. Cell Biol. 4 2003 915 925
40. P.C. Ma, G. Maulik, J. Christensen, and R. Salgia c-Met: structure, functions and potential for therapeutic inhibition Cancer Metastatis Rev. 22 2003 309 325
41. L. Trusolino, and P.M. Comoglio Scatter-factor and semaphorin receptors: cell signalling for invasive growth Nat. Rev. Cancer 2 2002 289 300
42. G. Maulik, A. Shrikhande, T. Kijima, P.C. Ma, P.T. Morrison, and R. Salgia Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev. 13 2002 41 59
43. A. Moghul, L. Lin, A. Beedle, A. Kanbour-Shakir, M.C. DeFrances, Y. Liu, and R. Zarnegar Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript Oncogene 9 1994 2045 2052
44. K.A. Furge, D. Kiewlich, P. Le, M.N. Vo, M. Faure, and A.R. Howlett Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase Proc. Natl Acad. Sci. USA 98 2001 10722 10727
45. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P.M. Comoglio Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell. 3 2003 347 361
46. H. Kuniyasu, W. Yasui, Y. Kitadai, H. Yokozaki, H. Ito, and E. Tahara Frequent amplification of the c-met gene in scirrhous type stomach cancer Biochem. Biophys. Res. Commun. 189 1992 227 232
47. M.F. Di Renzo, M. Olivero, A. Giacomini, H. Porte, E. Chastre, and L. Mirossay Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer Clin. Cancer Res. 1 1995 147 154
48. T. Hara, A. Ooi, M. Kobayashi, M. Mai, K. Yanagihara, and I. Nakanishi Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization Lab. Invest. 78 1998 1143 1153
49. B. Wullich, H.P. Sattler, U. Fischer, and E. Meese Two independent amplification events on chromosome 7 in glioma: amplification of the epidermal growth factor receptor gene and amplification of the oncogene MET Anticancer Res. 14 1994 577 579
50. K. Matsumoto, K. Date, H. Shimura, and T. Nakamura Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor Jpn. J. Cancer Res. 87 1996 702 710
51. K. Matsumoto, K. Date, H. Ohmichi, and T. Nakamura Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions Cancer Chemother. Pharmacol. 38 1996 S42 S47
52. K. Matsumoto, and T. Nakamura Emerging multipotent aspects of hepatocyte growth factor J. Biochem. 119 1996 591 600
53. T. Nakamura, K. Matsumoto, A. Kiritoshi, and Y. Tano Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions Cancer Res. 57 1997 3305 3313
54. E. Gohda, T. Matsunaga, H. Kataoka, T. Takebe, and I. Yamamoto Induction of hepatocyte growth factor in human skin fibroblasts by epidermal growth factor, platelet-derived growth factor and fibroblast growth factor Cytokine 6 1994 633 640
55. M. Tamura, N. Arakaki, H. Tsubouchi, H. Takada, and Y. Daikuhara Enhancement of human hepatocyte growth factor production by interleukin-1 alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture J. Biol. Chem. 268 1993 8140 8145
56. A.B. Tuck, M. Park, E.E. Sterns, A. Boag, and B.E. Elliott Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma Am. J. Pathol. 148 1996 225 232
57. J. Yamashita, M. Ogawa, S. Yamashita, K. Nomura, M. Kuramoto, T. Saishoji, and S. Shin Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer Cancer Res. 54 1994 1630 1633
58. Y. Taniguchi, N. Yorioka, K. Yamashita, Y. Xue-Feng, T. Nishiki, and T. Ogawa Localization of hepatocyte growth factor and tubulointerstitial lesions in IgA nephropathy Am. J. Nephrol. 17 1997 413 416
59. T. Moriyama, H. Kataoka, H. Tsubouchi, and M. Koono Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro Fed. Eur. Biochem. Soc. Lett. 372 1995 78 82
60. J.Y. Ljubimova, L.M. Petrovic, S.E. Wilson, S.A. Geller, and A.A. Demetriou Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue J. Histochem. Cytochem. 45 1997 79 87
61. J.M. Siegfried, L.A. Weissfeld, P. Singh-Kaw, R.J. Weyant, J.R. Testa, and R.J. Landreneau Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer Cancer Res. 57 1997 433 439
62. T. Furukawa, W.P. Duguid, M. Kobari, S. Matsuno, and M.S. Tsao Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis Am. J. Pathol. 147 1995 889 895
63. R. Ferracini, M.F. Di Renzo, K. Scotlandi, N. Baldini, M. Olivero, and P. Lollini The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit Oncogene 10 1995 739 749
64. M. Borset, E. Lien, T. Espevik, E. Helseth, A. Waage, and A. Sundan Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines J. Biol. Chem. 271 1996 24655 24661
65. R. Wang, L.D. Ferrell, S. Faouzi, J.J. Maher, and J.M. Bishop Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice J. Cell Biol. 153 2001 1023 1034
66. V. Wallenius, M. Hisaoka, K. Helou, G. Levan, N. Mandahl, and J.M. Meis-Kindblom Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors Am. J. Pathol. 156 2000 821 829
67. M. Prat, T. Crepaldi, L. Gandino, S. Giordano, P. Longati, and P. Comoglio C-terminal truncated forms of Met, the hepatocyte growth factor receptor Mol. Cell. Biol. 11 1991 5954 5962
68. M. Park, M. Dean, C.S. Cooper, M. Schmidt, S.J. O'Brien, D.G. Blair, and G.F. Vande Woude Mechanism of met oncogene activation Cell 45 1986 895 904
69. A. Follenzi, S. Bakovic, P. Gual, M.C. Stella, P. Longati, and P.M. Comoglio Cross-talk between the proto-oncogenes Met and Ron Oncogene 19 2000 3041 3049
70. M. Jo, D.B. Stolz, J.E. Esplen, K. Dorko, G.K. Michalopoulos, and S.C. Strom Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells J. Biol. Chem. 275 2000 8806 8811
71. R.R. Oh, J.Y. Park, J.H. Lee, M.S. Shin, H.S. Kim, and S.K. Lee Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas Acta Pathol. Microbiol. Immunol. Scand. 110 2002 229 238
72. L. Schmidt, F.M. Duh, F. Chen, T. Kishida, G. Glenn, and P. Choyke Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat. Genet. 16 1997 68 73
73. L. Schmidt, K. Junker, G. Weirich, G. Glenn, P. Choyke, and I. Lubensky Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene Cancer Res. 58 1998 1719 1722
74. J.H. Lee, S.U. Han, H. Cho, B. Jennings, B. Gerrard, and M. Dean A novel germ line juxtamembrane Met mutation in human gastric cancer Oncogene 19 2000 4947 4953
75. W.S. Park, S.M. Dong, S.Y. Kim, E.Y. Na, M.S. Shin, and J.H. Pi Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas Cancer Res. 59 1999 307 310
76. J. Tanyi, K. Tory, J. Rigo Jr, B. Nagy, and Z. Papp Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas* Pathol. Oncol. Res. 5 1999 187 191
77. P.C. Ma, T. Kijima, G. Maulik, E.A. Fox, M. Sattler, and J.D. Griffin c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions Cancer Res. 63 2003 6272 6281
78. P.C. Ma, S. Jagdeesh, R. Jagadeeswaran, E.A. Fox, J.G. Christensen, and G. Maulik c-MET expression/activation, functions, and mutations in non-small cell lung cancer Proc. Am. Assoc. Cancer Res. 44 2004 1875
79. M. Kong-Beltran, J. Stamos, and D. Wickramasinghe The Sema domain of Met is necessary for receptor dimerization and activation Cancer Cell 6 2004 75 84
80. J. Stamos, R.A. Lazarus, X. Yao, D. Kirchhofer, and C. Wiesmann Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor Eur. Mol. Biol. Org. J. 23 2004 2325 2335
81. M.F. Di Renzo, M. Olivero, T. Martone, A. Maffe, P. Maggiora, and A.D. Stefani Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas Oncogene 19 2000 1547 1555
82. D.M. Aebersold, O. Landt, S. Berthou, G. Gruber, K.T. Beer, R.H. Greiner, and Y. Zimmer Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx Oncogene 22 2003 8519 8523
83. A. Lorenzato, M. Olivero, S. Patane, E. Rosso, A. Oliaro, P.M. Comoglio, and M.F. Di Renzo Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion Cancer Res. 62 2002 7025 7030
84. Z.-S. Zeng, G.M. Nash, M. Gimbel, D.R. Nathanson, A.T. Culliford, and M. D'Alessio, Comparative analysis of c-Met gene amplification in primary colorectal cancer and liver metastasis using PCR/LDR assay Proc. Am. Assoc. Cancer Res. 44 2004 5075
85. L. Jin, A. Fuchs, S.J. Schnitt, Y. Yao, A. Joseph, and K. Lamszus Expression of scatter factor and c-met receptor in benign and malignant breast tissue Cancer 79 1997 749 760
86. L. Beviglia, K. Matsumoto, C.S. Lin, B.L. Ziober, and R.H. Kramer Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression Int. J. Cancer 74 1997 301 309
87. G. Edakuni, E. Sasatomi, T. Satoh, O. Tokunaga, and K. Miyazaki Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma Pathol. Int. 51 2001 172 178
88. I. Tsarfaty, W.G. Alvord, J.H. Resau, R.T. Altstock, R. Lidereau, and I. Bieche Alteration of Met protooncogene product expression and prognosis in breast carcinomas Anal. Quant. Cytol. Histol. 21 1999 397 408
89. E. Ichimura, A. Maeshima, T. Nakajima, and T. Nakamura Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance Jpn. J. Cancer Res. 87 1996 1063 1069
90. Y. Yonemura, M. Kaji, and Y. Hirono Correlation between overexpression of c-met and the progression of gastric cancer Int. J. Oncol. 8 1996 555 560
91. C.W. Wu, C.W. Chi, T.L. Su, T.Y. Liu, W.Y. Lui, and F.K. P'eng Serum hepatocyte growth factor level associate with gastric cancer progression Anticancer Res. 18 1998 3657 3659
92. D.M. Aebersold, A. Kollar, K.T. Beer, J. Laissue, R.H. Greiner, and V. Djonov Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation Int. J. Cancer 96 2001 41 54
93. T. Ueki, J. Fujimoto, T. Suzuki, H. Yamamoto, and E. Okamoto Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma Hepatology 25 1997 862 866
94. T. Iwasaki, T. Hamano, A. Ogata, N. Hashimoto, M. Kitano, and E. Kakishita Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma [see comment] Br. J. Haematol. 116 2002 796 802
95. C. Seidel, M. Borset, I. Turesson, N. Abildgaard, A. Sundan, and A. Waage Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group Blood 91 1998 806 812
96. T. Ueki, J. Fujimoto, T. Suzuki, H. Yamamoto, and E. Okamoto Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma Hepatology 25 1997 619 623
97. E.H. Ng, H.B. Pey, H.Y. Law, I. Ng, C.Y. Ji, V. Lin, and K.C. Soo Loss of c-met protooncogene in primary and metastatic sites of breast cancer Ann. Surg. Oncol. 4 1997 499 502
98. P.G. Natali, M.R. Nicotra, M.F. Di Renzo, M. Prat, A. Bigotti, R. Cavaliere, and P.M. Comoglio Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression Br. J. Cancer 68 1993 746 750
99. S. Koochekpour, M. Jeffers, S. Rulong, G. Taylor, E. Klineberg, and E.A. Hudson Met and hepatocyte growth factor/scatter factor expression in human gliomas Cancer Res. 57 1997 5391 5398
100. J.M. Siegfried, L.A. Weissfeld, J.D. Luketich, R.J. Weyant, C.T. Gubish, and R.J. Landreneau The clinical significance of hepatocyte growth factor for non-small cell lung cancer Ann. Thorac. Surg. 66 1998 1915 1918
101. D. Uchida, H. Kawamata, F. Omotehara, K. Nakashiro, T. Kimura-Yanagawa, and S. Hino Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance Int. J. Cancer 93 2001 489 496
102. S. Rong, S. Segal, M. Anver, J.H. Resau, and G.F. Vande Woude Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation Proc. Natl Acad. Sci. USA 91 1994 4731 4735
103. S. Rong, M. Bodescot, D. Blair, J. Dunn, T. Nakamura, and K. Mizuno Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor Mol. Cell. Biol. 12 1992 5152 5158
104. E.M. Rosen, A. Joseph, L. Jin, S. Rockwell, J.A. Elias, and J. Knesel Regulation of scatter factor production via a soluble inducing factor J. Cell Biol. 127 1994 225 234
105. M. Jeffers, M.S. Rao, S. Rulong, J.K. Reddy, V. Subbarao, and E. Hudson Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells Cell Growth Differ. 7 1996 1805 1813
106. M. Jeffers, S. Rong, and G.F. Woude Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis J. Mol. Med. 74 1996 505 513
107. K. Lamszus, L. Jin, A. Fuchs, E. Shi, S. Chowdhury, and Y. Yao Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice Lab. Invest. 76 1997 339 353
108. M. Jeffers, L. Schmidt, N. Nakaigawa, C.P. Webb, G. Weirich, and T. Kishida Activating mutations for the met tyrosine kinase receptor in human cancer Proc. Natl Acad. Sci. USA 94 1997 11445 11450
109. M. Jeffers, M. Fiscella, C.P. Webb, M. Anver, S. Koochekpour, and G.F. Vande Woude The mutationally activated Met receptor mediates motility and metastasis Proc. Natl Acad. Sci. USA 95 1998 14417 14422
110. M. Sattler, Y.B. Pride, P. Ma, J.L. Gramlich, S.C. Chu, and L.A. Quinnan A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase Cancer Res. 63 2003 5462 5469
111. H. Takayama, W.J. LaRochelle, R. Sharp, T. Otsuka, P. Kriebel, and M. Anver Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor Proc. Natl Acad. Sci. USA 94 1997 701 706
112. T. Otsuka, H. Takayama, R. Sharp, G. Celli, W.J. LaRochelle, and D.P. Bottaro c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype Cancer Res. 58 1998 5157 5167
113. M.I. Gallego, B. Bierie, and L. Hennighausen Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways Oncogene 22 2003 8498 8508
114. N. Horiguchi, H. Takayama, M. Toyoda, T. Otsuka, T. Fukusato, and G. Merlino Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine Oncogene 21 2002 1791 1799
115. F.P. Noonan, T. Otsuka, S. Bang, M.R. Anver, and G. Merlino Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice Cancer Res. 60 2000 3738 3743
116. J.A. Recio, F.P. Noonan, H. Takayama, M.R. Anver, P. Duray, and W.L. Rush Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis Cancer Res. 62 2002 6724 6730
117. R. Sharp, J.A. Recio, C. Jhappan, T. Otsuka, S. Liu, and Y. Yu Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis [see comment] [erratum appears in Nat. Med. 2003 Jan;9(1):146] Nat. Med. 8 2002 1276 1280
118. C.R. Graveel, Y. Su, L.M. Wang, M. Fiscella, T. Lino, and C. Birchmeier Tumorigenic effects of activating Met mutations in a knock-in mouse model Proc. Am. Assoc. Cancer Res. 44 2004 5102
119. T.J. Liang, A.E. Reid, R. Xavier, R.D. Cardiff, and T.C. Wang Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors J. Clin. Invest. 97 1996 2872 2877
120. Y. Nakamura, R. Morishita, J. Higaki, I. Kida, M. Aoki, and A. Moriguchi Expression of local hepatocyte growth factor system in vascular tissues Biochem. Biophys. Res. Commun. 215 1995 483 488
121. F. Bussolino, M.F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, and L. Naldini Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth J. Cell Biol. 119 1992 629 641
122. E.M. Rosen, W. Carley, and I.D. Goldberg Scatter factor regulates vascular endothelial cell motility Cancer Invest. 8 1990 647 650
123. E.M. Rosen, D. Grant, H. Kleinman, S. Jaken, M.A. Donovan, and E. Setter Scatter factor stimulates migration of vascular endothelium and capillary-like tube formation Supplementum to Experientia 59 1991 76 88
124. E.M. Rosen, L. Meromsky, E. Setter, D.W. Vinter, and I.D. Goldberg Purified scatter factor stimulates epithelial and vascular endothelial cell migration Proc. Soc. Exp. Biol. Med. 195 1990 34 43
125. D.S. Grant, H.K. Kleinman, I.D. Goldberg, M.M. Bhargava, B.J. Nickoloff, and J.L. Kinsella Scatter factor induces blood vessel formation in vivo Proc. Natl Acad. Sci. USA 90 1993 1937 1941
126. G. Dong, Z. Chen, Z.Y. Li, N.T. Yeh, C.C. Bancroft, and C. Van Waes Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma Cancer Res. 61 2001 5911 5918
127. J. Gille, M. Khalik, V. Konig, and R. Kaufmann Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes J. Invest. Dermatol. 111 1998 1160 1165
128. E. Van Belle, B. Witzenbichler, D. Chen, M. Silver, L. Chang, R. Schwall, and J.M. Isner Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis Circulation 97 1998 381 390
129. Y.W. Zhang, Y. Su, O.V. Volpert, and G.F. Vande Woude Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation Proc. Natl Acad. Sci. USA 100 2003 12718 12723
130. J. Wojta, C. Kaun, J.M. Breuss, Y. Koshelnick, R. Beckmann, and E. Hattey Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells Lab. Invest. 79 1999 427 438
131. X. Xin, S. Yang, G. Ingle, C. Zlot, L. Rangell, and J. Kowalski Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Am. J. Pathol. 158 2001 1111 1120
132. A. Morimoto, K. Tada, Y. Nakayama, K. Kohno, S. Naito, M. Ono, and M. Kuwano Cooperative roles of hepatocyte growth factor and plasminogen activator in tubular morphogenesis by human microvascular endothelial cells Jpn. J. Cancer Res. 85 1994 53 62
133. J. Laterra, E. Rosen, M. Nam, S. Ranganathan, K. Fielding, and P. Johnston Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth Biochem. Biophys. Res. Commun. 235 1997 743 747
134. E. Tolnay, C. Kuhnen, T. Wiethege, J.E. Konig, B. Voss, and K.M. Muller Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma J. Cancer Res. Clin. Oncol. 124 1998 291 296
135. R. Abounader, S. Ranganathan, B. Lal, K. Fielding, A. Book, and H. Dietz Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression J. Natl Cancer Inst. 91 1999 1548 1556
136. M.H. Herynk, O. Stoeltzing, N. Reinmuth, N.U. Parikh, R. Abounader, and J. Laterra Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells Cancer Res. 63 2003 2990 2996
137. O. Kaplan, M. Firon, A. Vivi, G. Navon, and I. Tsarfaty HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells Neoplasia (New York) 2 2000 365 377
138. C.P. Webb, G.A. Taylor, M. Jeffers, M. Fiscella, M. Oskarsson, J.H. Resau, and G.F. VandeWoude Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis Oncogene 17 1998 2019 2025
139. A. Bardelli, P. Longati, D. Gramaglia, C. Basilico, L. Tamagnone, and S. Giordano Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth Proc. Natl Acad. Sci. USA 95 1998 14379 14383
140. N. Atabey, Y. Gao, Z.J. Yao, D. Breckenridge, L. Soon, and J.V. Soriano Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions J. Biol. Chem. 276 2001 14308 14314
141. P. Michieli, M. Mazzone, C. Basilico, S. Cavassa, A. Sottile, L. Naldini, and P.M. Comoglio Targeting the tumor and its microenvironment by a dual-function decoy Met receptor Cancer Cell 6 2004 61 73
142. K. Date, K. Matsumoto, H. Shimura, M. Tanaka, and T. Nakamura HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor Fed. Eur. Biochem. Soc. Lett. 420 1997 1 6
143. K. Matsumoto, and T. Nakamura NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics Cancer Sci. 94 2003 321 327
144. K. Kuba, K. Matsumoto, K. Date, H. Shimura, M. Tanaka, and T. Nakamura HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice Cancer Res. 60 2000 6737 6743
145. K. Date, K. Matsumoto, K. Kuba, H. Shimura, M. Tanaka, and T. Nakamura Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor Oncogene 17 1998 3045 3054
146. D. Tomioka, N. Maehara, K. Kuba, K. Mizumoto, M. Tanaka, K. Matsumoto, and T. Nakamura Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model Cancer Res. 61 2001 7518 7524
147. G. Davies, M.D. Mason, T.A. Martin, C. Parr, G. Watkins, and J. Lane The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo Int. J. Cancer 106 2003 348 354
148. T.A. Martin, C. Parr, G. Davies, G. Watkins, J. Lane, and K. Matsumoto Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist Carcinogenesis 24 2003 1317 1323
149. Y. Saga, H. Mizukami, M. Suzuki, M. Urabe, A. Kume, and T. Nakamura Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival Gene Ther. 8 2001 1450 1455
150. M. Saimura, E. Nagai, K. Mizumoto, N. Maehara, H. Okino, and M. Katano Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice Cancer Gene Ther. 9 2002 799 806
151. M. Maemondo, K. Narumi, Y. Saijo, K. Usui, M. Tahara, and R. Tazawa Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy Mol. Ther. 5 2002 177 185
152. S. Hirao, Y. Yamada, F. Koyama, H. Fujimoto, Y. Takahama, and M. Ueno Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas Cancer Gene Ther. 9 2002 700 707
153. M. Nakabayashi, R. Morishita, H. Nakagami, K. Kuba, K. Matsumoto, and T. Nakamura HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model Diabetologia 46 2003 115 123
154. K. Kuba, K. Matsumoto, K. Ohnishi, T. Shiratsuchi, M. Tanaka, and T. Nakamura Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells Biochem. Biophys. Res. Commun. 279 2000 846 852
155. B. Cao, Y. Su, M. Oskarsson, P. Zhao, E.J. Kort, and R.J. Fisher Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models Proc. Natl Acad. Sci. USA 98 2001 7443 7448
156. Z. Zheng, C. Adams, B. Moffat, and R. Schwall A chimeric Fab antibody serves as an antagonist to the HGF/SF receptor c-Met Proc. Am. Assoc. Cancer Res. 43 2003 5717
157. P.A. Morton, W.D. Joy, C.P. Bono, A. Arbuckle, M.L. Evans, and M.S. Huynh In vitro and in vivo activity of fully-human monoclonal antibody antagonists to c-Met protein tyrosine kinase Proc. Am. Assoc. Cancer Res. 43 2003 5604
158. R. Schwall, C.W. Adams, Z. Zheng, M. Romero, E. Mai, and B. Moffat Inhibition of cmet activation by a one-armed antibody Proc. Am. Assoc. Cancer Res. 44 2004 1424
159. L. Neckers, T. Schulte, and E. Mimnaugh Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity Invest. New Drugs 17 1999 361 373
160. C.P. Webb, C.D. Hose, S. Koochekpour, M. Jeffers, M. Oskarsson, and E. Sausville The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network Cancer Res. 60 2000 342 349
161. A. Morotti, S. Mila, P. Accornero, E. Tagliabue, and C. Ponzetto K252a inhibits the oncogenic properties of Met, the HGF receptor Oncogene 21 2002 4885 4893
162. N. Schiering, S. Knapp, M. Marconi, M.M. Flocco, J. Cui, and R. Perego Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a Proc. Natl Acad. Sci. USA 100 2003 12654 12659
163. J.G. Christensen, R. Schreck, J. Burrows, P. Kuruganti, E. Chan, and P. Le A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo Cancer Res. 63 2003 7345 7355
164. X. Wang, P. Le, C. Liang, J. Chan, D. Kiewlich, and T. Miller Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion Mol. Cancer Ther. 2 2003 1085 1092
165. F. Yasunari, N. Terufumi, T. Osawa, A. Miwa, K, Nakamura. Preparation of quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor as antitumor agents, WO 2003000660 A1, Kirin Beer Kabushiki, Japan, 2003.
166. S. Berthou, D.M. Aebersold, L.S. Schmidt, D. Stroka, C. Heigl, and B. Streit The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants Oncogene 2004 1 7
167. G. Maulik, P.C. Ma, M. Rajgor, S. Jagadeesh, E. Schaefer, and S. Shirazian c-Met pathway inhibition through a novel tyrosine kinase inhibitor in small cell lung cancer Proc. Am. Assoc. Cancer Res. 43 2003 6200
168. A. Khwaja, K. Lehmann, B.M. Marte, and J. Downward Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway J. Biol. Chem. 273 1998 18793 18801
169. A. Karihaloo, D.A. O'Rourke, C. Nickel, K. Spokes, and L.G. Cantley Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis J. Biol. Chem. 276 2001 9166 9173
170. N. Nakaigawa, G. Weirich, L. Schmidt, and B. Zbar Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src Oncogene 19 2000 2996 3002
171. Z.X. Liu, C.F. Yu, C. Nickel, S. Thomas, and L.G. Cantley Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association J. Biol. Chem. 277 2002 10452 10458
172. E.C. Koon, P.C. Ma, R. Salgia, J.G. Christensen, M.G. Muto, R.S. Berkowitz, and S.C. Mok Effect of a c-met specific ATP-competitive small-molecule (SU-MI-2) on human ovarian carcinoma cell growth, motility and invasion Proc. Am. Assoc. Cancer Res. 44 2004 5363
173. H. Hov, R.U. Holt, T.B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, and V. Baykov A selective c-Met inhibitor blocks an autocrine HGF growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells Clin. Cancer Res. 10 2004 6686 6694
174. R.V. Hay, B. Cao, R.S. Skinner, L.M. Wang, Y. Su, and J.H. Resau Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor Mol. Imaging 1 2002 56 62
175. M. Shaharabany, R. Abramovitch, T. Kushnir, G. Tsarfaty, M. Ravid-Megido, and J. Horev In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors Cancer Res. 61 2001 4873 4878
176. I. Takanami, F. Tanana, T. Hashizume, K. Kikuchi, Y. Yamamoto, T. Yamamoto, and S. Kodaira Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers Oncology 53 1996 392 397
177. M.S. Tsao, N. Liu, J.R. Chen, J. Pappas, J. Ho, and C. To Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers Lung Cancer 20 1998 1 16
178. M. Olivero, M. Rizzo, R. Madeddu, C. Casadio, S. Pennacchietti, and M.R. Nicotra Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas Br. J. Cancer 74 1996 1862 1868
179. C. Liu, and M.S. Tsao In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas Am. J. Pathol. 142 1993 1155 1162
180. L.P. Stabile, J.S. Lyker, L. Huang, and J.M. Siegfried Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy Gene Ther. 11 2004 325 335
181. H. Ajisaka, G. Nishimura, A. Tsuneda, H. Fujita, Y. Michiwa, and T. Kawamura The expression of cMET/hepatocyte growth factor receptor in colorectal cancer Jpn. J. Gastroenterol. 95 1998 750 754
182. H. Takeuchi, A. Bilchik, S. Saha, R. Turner, D. Wiese, and M. Tanaka c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases Clin. Cancer Res. 9 2003 1480 1488
183. L. Schmidt, K. Junker, N. Nakaigawa, T. Kinjerski, G. Weirich, and M. Miller Novel mutations of the MET proto-oncogene in papillary renal carcinomas Oncogene 18 1999 2343 2350
184. C. Parr, S. Hiscox, T. Nakamura, K. Matsumoto, and W.G. Jiang Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells Int. J. Cancer 85 2000 563 570
185. R.L. Camp, E.B. Rimm, and D.L. Rimm Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma Cancer 86 1999 2259 2265
186. L. Nakopoulou, H. Gakiopoulou, A. Keramopoulos, I. Giannopoulou, P. Athanassiadou, J. Mavrommatis, and P.S. Davaris c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma Histopathology 36 2000 313 325
187. J. Nagy, G.W. Curry, K.J. Hillan, I.C. McKay, E. Mallon, A.D. Purushotham, and W.D. George Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer Surg. Oncol. 5 1996 15 21
188. R.A. Ghoussoub, D.A. Dillon, T. D'Aquila, E.B. Rimm, E.R. Fearon, and D.L. Rimm Expression of c-met is a strong independent prognostic factor in breast carcinoma Cancer 82 1998 1513 1520
189. I. Bieche, M.H. Champeme, and R. Lidereau Infrequent mutations of the MET gene in sporadic breast tumours Int. J. Cancer 82 1999 908 910
190. W.G. Jiang, D. Grimshaw, J. Lane, T.A. Martin, R. Abounader, and J. Laterra A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells [erratum appears in Clin Cancer Res 2002 Jan;8(1):300 Note: Abounder R [corrected to Abounader R]] Clin. Cancer Res. 7 2001 2555 2562
191. S. Hiscox, C. Parr, T. Nakamura, K. Matsumoto, R.E. Mansel, and W.G. Jiang Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4 Breast Cancer Res. Treat. 59 2000 245 254
192. K. Inoue, M. Chikazawa, T. Karashima, T. Iiyama, M. Kamada, and T. Shuin Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma Acta Med. Okayama 52 1998 305 310
193. L.L. Pisters, P. Troncoso, H.E. Zhau, W. Li, A.C. von Eschenbach, and L.W. Chung c-met proto-oncogene expression in benign and malignant human prostate tissues J. Urol. 154 1995 293 298
194. P.A. Humphrey, X. Zhu, R. Zarnegar, P.E. Swanson, T.L. Ratliff, R.T. Vollmer, and M.L. Day Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma Am. J. Pathol. 147 1995 386 396
195. B.S. Knudsen, G.A. Gmyrek, J. Inra, D.S. Scherr, E.D. Vaughan, and D.M. Nanus High expression of the Met receptor in prostate cancer metastasis to bone Urology 60 2002 1113 1117
196. C. Parr, G. Davies, T. Nakamura, K. Matsumoto, M.D. Mason, and W.G. Jiang The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant Biochem. Biophys. Res. Commun. 285 2001 1330 1337
197. S. La Rosa, S. Uccella, C. Capella, S. Erba, and F. Sessa Localization of hepatocyte growth factor and its receptor met in endocrine cells and related tumors of the gut and pancreas: an immunohistochemical study Endocr. Pathol. 11 2000 315 329
198. R. Paciucci, M.R. Vila, T. Adell, V.M. Diaz, M. Tora, T. Nakamura, and F.X. Real Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. Am. J. Pathol. 153 1998 201 212
199. M.F. Di Renzo, R. Poulsom, M. Olivero, P.M. Comoglio, and N.R. Lemoine Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer Cancer Res. 55 1995 1129 1138
200. N. Maehara, K. Matsumoto, K. Kuba, K. Mizumoto, M. Tanaka, and T. Nakamura NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells Br. J. Cancer 84 2001 864 873
201. S. Wagatsuma, R. Konno, S. Sato, and A. Yajima Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma Cancer 82 1998 520 530
202. D. Huntsman, J.H. Resau, E. Klineberg, and N. Auersperg Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy Am. J. Pathol. 155 1999 343 348
203. M.F. Di Renzo, M. Olivero, D. Katsaros, T. Crepaldi, P. Gaglia, and P. Zola Overexpression of the Met/HGF receptor in ovarian cancer Int. J. Cancer 58 1994 658 662
204. M. Sawatsubashi, E. Sasatomi, H. Mizokami, O. Tokunaga, and T. Shin Expression of c-Met in laryngeal carcinoma Virchows Arch. 432 1998 331 335
205. K. Suzuki, J. Cheng, and Y. Watanabe Hepatocyte growth factor and c-Met (HGF/c-Met) in adenoid cystic carcinoma of the human salivary gland J. Oral Pathol. Med. 32 2003 84 89
206. E. Galeazzi, M. Olivero, F.C. Gervasio, A. De Stefani, G. Valente, and P.M. Comoglio Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas Eur. Arch. Otorhinolaryngol. 254 1997 S138 S143
207. C.N. Qian, X. Guo, B. Cao, E.J. Kort, C.C. Lee, and J. Chen Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma Cancer Res. 62 2002 589 596
208. A. Kiss, N.J. Wang, J.P. Xie, and S.S. Thorgeirsson Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas Clin. Cancer Res. 3 1997 1059 1066
209. K. Suzuki, N. Hayashi, Y. Yamada, H. Yoshihara, Y. Miyamoto, and Y. Ito Expression of the c-met protooncogene in human hepatocellular carcinoma Hepatology 20 1994 1231 1236
210. K. Nabeshima, Y. Shimao, S. Sato, H. Kataoka, T. Moriyama, and H. Kawano Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study Histopathology 31 1997 436 443
211. Y. Hirose, M. Kojima, M. Sagoh, H. Murakami, K. Yoshida, K. Shimazaki, and T. Kawase Immunohistochemical examination of c-Met protein expression in astrocytic tumors Acta Neuropathol. 95 1998 345 351
212. Y.W. Moon, R.J. Weil, S.D. Pack, W.S. Park, E. Pak, and T. Pham Missense mutation of the MET gene detected in human glioma Mod. Pathol. 13 2000 973 977
213. R. Abounader, B. Lal, C. Luddy, G. Koe, B. Davidson, E.M. Rosen, and J. Laterra In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis Fed. Am. Soc. Exp. Biol. J. 16 2002 108 110
214. L. Nakopoulou, C. Vouriakou, E. Papaliodi, A.C. Lazaris, K. Stefanaski, and G. Michalopoulos Immunodetection of c-met-oncogene's protein product in renal cell neoplasia Pathol. Res. Pract. 193 1997 299 304
215. P. Sweeney, A.K. El-Naggar, S.H. Lin, and L.L. Pisters Biological significance of c-met over expression in papillary renal cell carcinoma J. Urol. 168 2002 51 55
216. P.G. Natali, M. Prat, M.R. Nicotra, A. Bigotti, M. Olivero, P.M. Comoglio, and M.F. Di Renzo Overexpression of the met/HGF receptor in renal cell carcinomas Int. J. Cancer 69 1996 212 217
217. K. Inoue, T. Karashima, M. Chikazawa, T. Iiyama, C. Yoshikawa, and M. Furihata Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth Virchows Arch. 433 1998 511 515
218. W.S. Park, R.R. Oh, Y.S. Kim, J.Y. Park, M.S. Shin, and H.K. Lee Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas Acta Pathol. Microbiol. Immunol. Scand. 108 2000 195 200
219. C.W. Wu, A.F. Li, C.W. Chi, W.W. Chung, T.Y. Liu, W.Y. Lui, and F.K. P'eng Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma Oncol. Rep. 5 1998 817 822
220. M. Nakajima, H. Sawada, Y. Yamada, A. Watanabe, M. Tatsumi, and J. Yamashita The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas [see comment] Cancer 85 1999 1894 1902
221. K. Taniguchi, Y. Yonemura, N. Nojima, Y. Hirono, S. Fushida, and T. Fujimura The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor Cancer 82 1998 2112 2122
222. K. Tsugawa, Y. Yonemura, Y. Hirono, S. Fushida, M. Kaji, and K. Miwa Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features Oncology 55 1998 475 481
223. C. Gao, and Y. Lu Correlation of multiple gene changes with malignant phenotype of human gastric carcinoma Chung-Hua i Hsueh Tsa Chih 76 1996 671 675
224. M. Kaji, Y. Yonemura, S. Harada, X. Liu, I. Terada, and H. Yamamoto Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells Cancer Gene Ther. 3 1996 393 404